RACQUEL GALVAN: Open Payments
NPI 1083488308 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,224 in 63 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $264 · 2025 $1,224
Food & beverage: $1,224
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $403 |
| Novo Nordisk Inc | 10 | $193 |
| AstraZeneca Pharmaceuticals LP | 5 | $168 |
| Astellas Pharma US Inc | 4 | $78 |
| TOLMAR, INC. | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
Products named: QULIPTA, BREZTRI, VRAYLAR, UBRELVY, Ozempic, Veozah, Wegovy, JATENZO.
Industry payments across AZ — which companies pay providers there.
